Interpace Biosciences (IDXG)
(Delayed Data from OTC)
$1.50 USD
+0.08 (5.45%)
Updated Apr 26, 2024 03:52 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Interpace Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 40 | 32 | 41 | 32 | 24 |
Cost Of Goods | 16 | 14 | 23 | 22 | 16 |
Gross Profit | 24 | 18 | 18 | 11 | 8 |
Selling & Adminstrative & Depr. & Amort Expenses | 21 | 22 | 32 | 37 | 35 |
Income After Depreciation & Amortization | 3 | -4 | -14 | -26 | -26 |
Non-Operating Income | -2 | -2 | -1 | 0 | 0 |
Interest Expense | 0 | 0 | 1 | 1 | 0 |
Pretax Income | 1 | -6 | -15 | -26 | -27 |
Income Taxes | 0 | 0 | -1 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 1 | -6 | -15 | -26 | -27 |
Extras & Discontinued Operations | 0 | -16 | 0 | 0 | 0 |
Net Income (GAAP) | 1 | -22 | -15 | -26 | -27 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 4 | 7 | -8 | -21 | -22 |
Depreciation & Amortization (Cash Flow) | 2 | 11 | 6 | 6 | 4 |
Income After Depreciation & Amortization | 3 | -4 | -14 | -26 | -26 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.36 | 4.24 | NA | 4.03 | 3.75 |
Diluted EPS Before Non-Recurring Items | 0.25 | -1.38 | NA | -7.26 | -5.58 |
Diluted Net EPS (GAAP) | 0.18 | -5.18 | -3.61 | -7.32 | -7.25 |
Fiscal Year end for Interpace Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 10.28 | 9.08 | 11.03 | 9.83 |
Cost Of Goods | NA | 4.15 | 4.12 | 4.19 | 3.85 |
Gross Profit | NA | 6.14 | 4.95 | 6.84 | 5.98 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 4.82 | 4.97 | 6.01 | 5.30 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1.32 | -0.02 | 0.83 | 0.68 |
Non-Operating Income | NA | -0.38 | -0.51 | -0.43 | -0.24 |
Interest Expense | NA | 0.11 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | 0.82 | -0.52 | 0.40 | 0.43 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 0.82 | -0.53 | 0.40 | 0.43 |
Extras & Discontinued Operations | NA | 0.08 | -0.09 | -0.22 | -0.08 |
Net Income (GAAP) | NA | 0.89 | -0.61 | 0.18 | 0.35 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 4.32 | 4.31 | 4.31 |
Diluted EPS Before Non-Recurring Items | NA | NA | -0.12 | 0.09 | 0.10 |
Diluted Net EPS (GAAP) | NA | 0.20 | -0.14 | 0.04 | 0.08 |